| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
Departments of 1 Internal Medicine, 2 Pathology, and 3 Urology, University of Michigan Medical School, Ann Arbor, Michigan
Requests for reprints: Theodora S. Ross, University of Michigan, 6322 CCGC, 1500 East Medical Center Drive, Ann Harbor, MI 48109-0942. Phone: 734-615-5509; E-mail: tsross{at}umich.edu.
Huntingtin-interacting protein 1 (HIP1) is frequently overexpressed in prostate cancer. HIP1 is a clathrin-binding protein involved in growth factor receptor trafficking that transforms fibroblasts by prolonging the half-life of growth factor receptors. In addition to human cancers, HIP1 is also overexpressed in prostate tumors from the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model. Here we provide evidence that HIP1 plays an important role in mouse tumor development, as tumor formation in the TRAMP mice was impaired in the Hip1null/null background. In addition, we report that autoantibodies to HIP1 developed in the sera of TRAMP mice with prostate cancer as well as in the sera from human prostate cancer patients. This led to the development of an anti-HIP1 serum test in humans that had a similar sensitivity and specificity to the anti–
-methylacyl CoA racemase (AMACR) and prostate-specific antigen tests for prostate cancer and when combined with the anti-AMACR test yielded a specificity of 97%. These data suggest that HIP1 plays a functional role in tumorigenesis and that a positive HIP1 autoantibody test may be an important serum marker of prostate cancer.
This article has been cited by other articles:
|
|
 |
|
  B. Lin, A. G. Utleg, K. Gravdal, J. T. White, O. J. Halvorsen, W. Lu, L. D. True, R. Vessella, P. H. Lange, P. S. Nelson, et al. WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence Clin. Cancer Res., March 1, 2008; 14(5): 1397 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Graves, S. T. Philips, S. V. Bradley, K. I. Oravecz-Wilson, L. Li, A. Gauvin, and T. S. Ross Use of a Cryptic Splice Site for the Expression of Huntingtin Interacting Protein 1 in Select Normal and Neoplastic Tissues Cancer Res., February 15, 2008; 68(4): 1064 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Bradley, M. R. Smith, T. S. Hyun, P. C. Lucas, L. Li, D. Antonuk, I. Joshi, F. Jin, and T. S. Ross Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies Cancer Res., September 15, 2007; 67(18): 8923 - 8931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Bradley, T. S. Hyun, K. I. Oravecz-Wilson, L. Li, E. I. Waldorff, A. N. Ermilov, S. A. Goldstein, C. X. Zhang, D. G. Drubin, K. Varela, et al. Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1 Hum. Mol. Genet., June 1, 2007; 16(11): 1279 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Bradley, E. C. Holland, G. Y. Liu, D. Thomas, T. S. Hyun, and T. S. Ross Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor Cancer Res., April 15, 2007; 67(8): 3609 - 3615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer Mol. Cell. Proteomics, October 1, 2006; 5(10): 1745 - 1759. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
